CN113134080A - 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 - Google Patents

抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 Download PDF

Info

Publication number
CN113134080A
CN113134080A CN202010052280.6A CN202010052280A CN113134080A CN 113134080 A CN113134080 A CN 113134080A CN 202010052280 A CN202010052280 A CN 202010052280A CN 113134080 A CN113134080 A CN 113134080A
Authority
CN
China
Prior art keywords
cancer
antibody
seq
amino acid
furoquintinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010052280.6A
Other languages
English (en)
Chinese (zh)
Inventor
闫洪滨
王斯斯
谢帆
戴秋曦
陈文会
王倩
郭倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENOR BIOPHARMA CO Ltd
Hutchmed Ltd
Original Assignee
GENOR BIOPHARMA CO Ltd
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOR BIOPHARMA CO Ltd, Hutchison Medipharma Ltd filed Critical GENOR BIOPHARMA CO Ltd
Priority to CN202010052280.6A priority Critical patent/CN113134080A/zh
Priority to PCT/CN2021/071996 priority patent/WO2021143799A1/fr
Priority to CN202180008488.0A priority patent/CN115003332A/zh
Publication of CN113134080A publication Critical patent/CN113134080A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202010052280.6A 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 Pending CN113134080A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202010052280.6A CN113134080A (zh) 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途
PCT/CN2021/071996 WO2021143799A1 (fr) 2020-01-17 2021-01-15 Utilisation d'un anticorps anti-pd-1 en combinaison avec du fruquintinib dans la préparation de médicaments pour le traitement du cancer
CN202180008488.0A CN115003332A (zh) 2020-01-17 2021-01-15 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010052280.6A CN113134080A (zh) 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Publications (1)

Publication Number Publication Date
CN113134080A true CN113134080A (zh) 2021-07-20

Family

ID=76808365

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010052280.6A Pending CN113134080A (zh) 2020-01-17 2020-01-17 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途
CN202180008488.0A Pending CN115003332A (zh) 2020-01-17 2021-01-15 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180008488.0A Pending CN115003332A (zh) 2020-01-17 2021-01-15 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途

Country Status (2)

Country Link
CN (2) CN113134080A (fr)
WO (1) WO2021143799A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114159557A (zh) * 2021-11-09 2022-03-11 北京东方百泰生物科技股份有限公司 一种治疗肿瘤疾病的联合用药组合物及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118660720A (zh) * 2022-02-22 2024-09-17 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201900571YA (en) * 2014-07-22 2019-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN111065411B (zh) * 2017-11-16 2023-03-10 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
CN110624106A (zh) * 2018-06-22 2019-12-31 嘉和生物药业有限公司 Pd-1信号通路拮抗剂与艾滋病疫苗的联合应用
CN112043702A (zh) * 2019-06-05 2020-12-08 正大天晴药业集团股份有限公司 用于联合治疗结直肠癌的喹啉类化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114159557A (zh) * 2021-11-09 2022-03-11 北京东方百泰生物科技股份有限公司 一种治疗肿瘤疾病的联合用药组合物及应用

Also Published As

Publication number Publication date
WO2021143799A1 (fr) 2021-07-22
CN115003332A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
TWI744617B (zh) 治療潰瘍性結腸炎之方法
WO2019096194A1 (fr) Utilisation d'un anticorps anti-pd-1 combiné à un inhibiteur de vegfr dans le traitement du cancer du poumon à petites cellules
JP2011511074A (ja) 結腸直腸癌を治療するためのピコプラチンおよびセツキシマブの使用
TWI818120B (zh) 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
WO2011014726A1 (fr) Polythérapie par inhibiteur de mtor et inhibiteur de l’angiogenèse
CN116437954A (zh) 用于治疗癌症的组合
WO2018072743A1 (fr) Utilisation d'un anticorps anti-pd-1 conjugué à un inhibiteur de l'ido dans la préparation d'un médicament antitumoral
Federico et al. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours
CN113134080A (zh) 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途
US20220332832A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
WO2020239085A1 (fr) Composition pharmaceutique combinée pour le traitement du mélanome
TWI817958B (zh) 用於治療肝癌之組合物及方法
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2022502411A (ja) 非小細胞肺がんの処置のためのａｘｌ特異的抗体
EP4159238A1 (fr) Composition pharmaceutique combinée d'inhibiteur de kinase c-met et d'anticorps anti-pd-l1
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
JP7556468B2 (ja) Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法
TWI775333B (zh) 治療癌症之方法
CN112915202A (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2023174278A1 (fr) Composition pharmaceutique d'anticorps anti-tim-3 et d'agent d'hypométhylation
RU2802962C2 (ru) Композиции и способы лечения рака печени
WO2024155790A2 (fr) Nouvelle approche dans le traitement du cancer à l'aide de l'immunomodulation
CN115779095A (zh) 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210720

WD01 Invention patent application deemed withdrawn after publication